MA51584A - Méthodes de traitement d'une inflammation médiée par il-6 sans immunosuppression - Google Patents

Méthodes de traitement d'une inflammation médiée par il-6 sans immunosuppression

Info

Publication number
MA51584A
MA51584A MA051584A MA51584A MA51584A MA 51584 A MA51584 A MA 51584A MA 051584 A MA051584 A MA 051584A MA 51584 A MA51584 A MA 51584A MA 51584 A MA51584 A MA 51584A
Authority
MA
Morocco
Prior art keywords
immunosuppression
inflammation
treating
media
methods
Prior art date
Application number
MA051584A
Other languages
English (en)
Inventor
Michael H Davidson
Madhav N Devalaraja
Rahul Kakkar
Original Assignee
Corvidia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvidia Therapeutics Inc filed Critical Corvidia Therapeutics Inc
Publication of MA51584A publication Critical patent/MA51584A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
MA051584A 2018-01-05 2019-01-04 Méthodes de traitement d'une inflammation médiée par il-6 sans immunosuppression MA51584A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862614134P 2018-01-05 2018-01-05

Publications (1)

Publication Number Publication Date
MA51584A true MA51584A (fr) 2020-11-11

Family

ID=67143789

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051584A MA51584A (fr) 2018-01-05 2019-01-04 Méthodes de traitement d'une inflammation médiée par il-6 sans immunosuppression

Country Status (20)

Country Link
US (4) US20190241650A1 (fr)
EP (1) EP3735421A4 (fr)
JP (2) JP7395479B2 (fr)
KR (2) KR20230047223A (fr)
CN (1) CN111787950A (fr)
AU (1) AU2019205936B2 (fr)
BR (1) BR112020013519A2 (fr)
CA (1) CA3087699A1 (fr)
CL (2) CL2020001790A1 (fr)
CO (1) CO2020009510A2 (fr)
EA (1) EA202091640A1 (fr)
IL (1) IL275696A (fr)
MA (1) MA51584A (fr)
MX (1) MX2020006882A (fr)
PE (1) PE20211196A1 (fr)
PH (1) PH12020551040A1 (fr)
RU (1) RU2020125805A (fr)
SG (1) SG11202006157VA (fr)
WO (1) WO2019136312A1 (fr)
ZA (1) ZA202004074B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144773A1 (fr) 2017-02-01 2018-08-09 Yale University Traitement de la résistance aux diurétiques
US20190241650A1 (en) 2018-01-05 2019-08-08 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
AU2020216978A1 (en) * 2019-01-31 2021-09-09 Regeneron Pharmaceuticals, Inc. Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
EP3962942A1 (fr) 2019-05-01 2022-03-09 Novo Nordisk A/S Formulation d'anticorps anti-il-6
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
AR122933A1 (es) * 2020-07-10 2022-10-19 Novo Nordisk As Métodos para tratar la enfermedad cardiovascular
WO2022167916A1 (fr) * 2021-02-03 2022-08-11 Novartis Ag Utilisation d'anticorps se liant à l'il-1b pour le traitement de troubles neuro-inflammatoires
JP7132665B1 (ja) * 2022-02-25 2022-09-07 株式会社 バイオミメティクスシンパシーズ 腫瘍を縮小又は消失させるための組成物

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399429A1 (fr) 1989-05-22 1990-11-28 Toray Industries, Inc. Anticorps monoclonal contre l'interleukine-6 humaine
JP2881311B2 (ja) 1989-07-28 1999-04-12 味の素株式会社 抗ヒトｂｃｄｆモノクローナル抗体及びそれを用いたヒトｂｃｄｆの定量法
TW458985B (en) 1993-05-31 2001-10-11 Chugai Pharmaceutical Co Ltd Reconstructed human antibody against human interleukin-6
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
WO1995033483A1 (fr) 1994-06-07 1995-12-14 Toray Industries, Inc. Agent preventif et curatif contre les maladies provoquees par la formation de fibrinoides ou de thrombus dans les poumons et modele animal pour ces maladies
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
JPH1066582A (ja) 1996-08-27 1998-03-10 Tosoh Corp Ｉｌ−６のヘリックスｄ領域を認識する抗体の遺伝子断片等
HU225539B1 (en) 1998-03-17 2007-02-28 Chugai Pharmaceutical Co Ltd Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient antibody against il-6 receptor
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
DE60024809D1 (de) * 1999-04-29 2006-01-19 Novo Nordisk As Verwendung von anti-hbp antikörper zur inhibierung der freisetzung von bradykinin
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
WO2002036164A1 (fr) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent abaissant le taux sanguin de vegf contenant un antagoniste de il-6 en tant que principe actif
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
EP2354149B1 (fr) 2000-12-12 2017-08-30 MedImmune, LLC Molécules à demi-vies longues, compositions et utilisations de celles-ci
EE200400042A (et) 2001-06-28 2004-10-15 Essential Therapeutics, Inc. 8/17 heterotsüklilised ühendid ning nende kasutamine D-alanüül-D-alaniini ligaasi inhibiitoritena
EP2308888B1 (fr) 2001-11-14 2017-03-01 Janssen Biotech, Inc. Anticorps anti-IL-6, compositions, méthodes et utilisations associées
EP1456347A4 (fr) 2001-11-16 2006-08-02 Human Genome Sciences Inc Anticorps se liant a blys selon un mode immunospecifique
FR2833011B1 (fr) 2001-12-04 2004-10-29 Univ Claude Bernard Lyon Nouvelle proteine a activite inhibitrice de l'il-6
JP2006512895A (ja) 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060078533A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
KR100442281B1 (ko) 2002-08-26 2004-08-02 엘지전자 주식회사 홈 네트워크 시스템의 제어 방법
US7482436B2 (en) 2002-08-30 2009-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of antibody
JP2006516957A (ja) 2002-11-15 2006-07-13 セントカー・インコーポレーテツド Ｉｌ−６アンタゴニストの抗血管形成用途
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
JP4960096B2 (ja) 2003-09-22 2012-06-27 ペントラコール ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−６の生物学的効果を減じる化合物の使用
BRPI0506679A (pt) 2004-02-11 2007-05-15 Warner Lambert Co métodos de tratar osteoartrite com antagonistas de il-6
WO2006072954A2 (fr) 2005-01-05 2006-07-13 Compugen Ltd. Nouveaux polynucleotides il-6 codant pour des polypeptides il-6 variants et leurs methodes d'utilisation
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
CA2608873C (fr) 2005-05-20 2017-04-25 Ablynx Nv Nanobodies (nanocorps) perfectionnes pour traiter des troubles medies par une agregation
WO2006130834A2 (fr) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System Molecules d'immunoglobuline ayant des proprietes ameliorees
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (fr) 2005-11-25 2007-05-31 Keio University Agent thérapeutique pour le cancer de la prostate
UA96141C2 (ru) 2005-12-09 2011-10-10 Юсиби Фарма, С.А. Нейтрализующее антитело, которое имеет специфичность к человеческому il-6
EP1977763A4 (fr) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Préparation stabilisatrice contenant des anticorps
ES2382164T3 (es) 2005-12-30 2012-06-05 Merck Patent Gmbh Anticuerpos anti-IL-6 que impiden la unión de la IL-6 en complejo con el IL-6R( ) a la GP130
EP2004690A2 (fr) 2006-03-13 2008-12-24 Ablynx N.V. Séquences d'acides aminés dirigées contre il-6 et polypeptides incluant lesdites séquences dans le traitement de maladies et de troubles associés au signalement faisant intervenir il-6
US7504106B2 (en) 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
CN101563365B (zh) 2006-08-03 2012-10-31 瓦西尼斯公司 抗-il-6单克隆抗体及其用途
CA2667466A1 (fr) 2006-10-27 2008-05-02 Ablynx N.V. Administration intranasale de polypeptides et de proteines
JP2010510796A (ja) 2006-11-30 2010-04-08 アストラゼネカ アクチボラグ インターロイキン−６とインターロイキン−６受容体との複合体に特異的な抗体
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
JP4966647B2 (ja) 2006-12-27 2012-07-04 矢崎総業株式会社 電気接続箱のシール構造
CL2008000058A1 (es) 2007-01-09 2008-05-23 Wyeth Corp Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden.
KR20100017514A (ko) 2007-05-07 2010-02-16 메디뮨 엘엘씨 항 ｉｃｏｓ 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
PT3187506T (pt) 2007-05-21 2019-04-24 Alderbio Holdings Llc Anticorpos contra il-6 e sua utilização
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US20090238825A1 (en) 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
NZ601583A (en) 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
WO2008156807A2 (fr) 2007-06-19 2008-12-24 The Johns Hopkins University Agents antithrombotiques et leurs procédés d'utilisation
US20110008329A1 (en) 2007-06-26 2011-01-13 Medlmmune, Llc Methods of Treating RSV Infections And Related Conditions
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8529897B2 (en) 2007-08-16 2013-09-10 Carnegie Mellon University Inflammation-regulating compositions and methods
US20100203009A1 (en) 2007-10-02 2010-08-12 The Uab Research Foundation Pathway for Th-17 Cell Development and Methods Utilizing Same
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN102089326B (zh) 2008-05-13 2014-12-31 诺维莫尼公司 抗白细胞介素-6/白细胞介素-6受体的抗体及其使用方法
US8277804B2 (en) 2008-05-21 2012-10-02 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
NZ602166A (en) 2008-11-25 2014-02-28 Alder Biopharmaceuticals Inc Antibodies to il-6 and use thereof
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
CN102387814A (zh) * 2009-01-29 2012-03-21 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
US20120294852A1 (en) * 2009-11-24 2012-11-22 Smith Jeffrey T L Antagonists of il-6 to raise albumin and/or lower crp
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US20130224109A1 (en) 2010-07-20 2013-08-29 Beth Israel Deaconess Medical Center, Inc. Compositions and methods featuring il-6 and il-21 antagonists
JP5918246B2 (ja) 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
BR112013011305A2 (pt) * 2010-11-08 2017-07-25 Chugai Pharmaceutical Co Ltd método de tratamento de uma disfunção mediada por il-6, método de tratamento de artrite reumatóide, artigo de fabricação, método de inibição da progressão de dano estrutural articular, composição farmacêutica, método de tratamento de artrite idiopática juvenil (jia) e método de tratamento de arterite de células gigantes (gca)
US20120189621A1 (en) 2011-01-21 2012-07-26 Yann Dean Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists
EP2681243B1 (fr) 2011-03-03 2018-09-05 Apexigen, Inc. Anticorps anti-récepteurs il-6 et leurs procédés d'utilisation
WO2013175276A1 (fr) 2012-05-23 2013-11-28 Argen-X B.V Molécules se liant à l'il-6
PE20151434A1 (es) 2012-10-22 2015-10-16 Stealth Peptides Int Inc Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo
BR112015008186A2 (pt) 2012-10-25 2017-09-19 Medimmune Llc formulação de um anticorpo estável e de baixa viscosidade
JP6487848B2 (ja) 2012-11-08 2019-03-20 クリアサイド バイオメディカル，インコーポレイテッド ヒト被験体における眼部障害の処置のための方法およびデバイス
SG11201502876RA (en) 2012-11-08 2015-06-29 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof
KR102218494B1 (ko) 2013-03-15 2021-02-19 인트린식 라이프사이언시스, 엘엘씨 항-헵시딘 항체 및 그의 용도
WO2015028657A1 (fr) * 2013-08-30 2015-03-05 Takeda Gmbh Anticorps neutralisant le gm-csf destiné à être utilisé dans le traitement de la polyarthrite rhumatoïde ou comme analgésique
US20160130340A1 (en) 2013-10-07 2016-05-12 Alderbio Holdings Llc Dosing regimens using anti-il-6 antibodies for the treatment of rheumatoid and psoriatic arthritis
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
CN113117074A (zh) 2015-07-31 2021-07-16 米迪缪尼有限公司 用于治疗海帕西啶介导的病症的方法
WO2018144773A1 (fr) 2017-02-01 2018-08-09 Yale University Traitement de la résistance aux diurétiques
US20190241650A1 (en) 2018-01-05 2019-08-08 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression

Also Published As

Publication number Publication date
KR20200116089A (ko) 2020-10-08
EA202091640A1 (ru) 2020-10-26
US20230090473A1 (en) 2023-03-23
PH12020551040A1 (en) 2021-08-23
AU2019205936A1 (en) 2020-07-23
WO2019136312A1 (fr) 2019-07-11
SG11202006157VA (en) 2020-07-29
US20220227856A1 (en) 2022-07-21
BR112020013519A2 (pt) 2020-12-01
MX2020006882A (es) 2020-09-07
ZA202004074B (en) 2022-03-30
AU2019205936B2 (en) 2022-09-15
CL2020001790A1 (es) 2021-03-19
KR20230047223A (ko) 2023-04-06
JP2023168447A (ja) 2023-11-24
JP7395479B2 (ja) 2023-12-11
EP3735421A4 (fr) 2021-09-22
JP2021509668A (ja) 2021-04-01
CO2020009510A2 (es) 2020-10-30
US20190248886A1 (en) 2019-08-15
CL2023001681A1 (es) 2023-12-15
CA3087699A1 (fr) 2019-07-11
US20190241650A1 (en) 2019-08-08
CN111787950A (zh) 2020-10-16
PE20211196A1 (es) 2021-07-01
EP3735421A1 (fr) 2020-11-11
US11384143B2 (en) 2022-07-12
RU2020125805A (ru) 2022-02-07
IL275696A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
MA51584A (fr) Méthodes de traitement d'une inflammation médiée par il-6 sans immunosuppression
MA49144A (fr) Polythérapies pour le traitement du cancer
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA52371A (fr) Méthodes de traitement d'infections dues aux coronaviridae
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
EA201792186A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
MA56212A (fr) Compositions et méthodes de traitement du cancer
MA52624A (fr) Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
MA50264A (fr) Méthodes de traitement des infections de type hépatite b
MA48637A (fr) Polythérapies pour le traitement du cancer
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
MA50409A (fr) Polythérapies pour le traitement du cancer
MA53329A (fr) Méthodes de traitement de l'épilepsie
MA53506A (fr) Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
MA54860A (fr) Méthodes de traitement du myélome multiple
MA51738A (fr) Composés pour le traitement de la douleur
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
MA52499A (fr) Associations pour le traitement du cancer
MA52627A (fr) Traitement du cancer
MA44864A (fr) Trithérapie pour le traitement d'une maladie intestinale inflammatoire
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire
MA51613A (fr) Polythérapie pour le traitement ou la prévention du cancer
MA54388A (fr) Méthodes de traitement du cancer résistant aux inhibiteurs cdk4/6
MA53481A (fr) Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde